Skip to content

Checked

Class IIDrug recallOngoing

IMAAVY (nipocalimab-aahu) Injection recall

Recalled by J&J INNOVATIVE MEDICINE of Malvern, PA · FDA report 10/14/2026

Not an official recall notice and may be delayed. Confirm with the manufacturer or the agency.

Class
Class II
Moderate
Status
Ongoing
Recall started
09/23/2026
Distribution
See below

Reason for recall

Presence of particulate matter.

Class II: Use of or exposure to the product may cause temporary or medically reversible health problems, or the chance of serious harm is remote.

Recalled product

Product
IMAAVY (nipocalimab-aahu) Injection, 300 mg /1.62 mL (185 mg/mL) per single-dose vial, For Intravenous Infusion After Dilution, Rx only, Manufactured by: Janssen Biotech, Inc., Horsham, PA 19044. NDC: 57894-800-01
Lot and code info
Lot JNYJ1208; Exp. 10/30/2027
Quantity
49 vials
Brand names
IMAAVY
Recall number
D-0016-2027
Event ID
99972
Initiated by
Voluntary: Firm initiated

Where it was distributed

OH

Recall timeline

  1. 09/23/2026Firm started the recall
  2. 10/08/2026FDA classified it as Class II
  3. 10/14/2026Published in the FDA enforcement report

Frequently asked questions

Why was IMAAVY (nipocalimab-aahu) Injection recalled?
Presence of particulate matter.
What does Class II mean?
Class II is FDA's moderate recall category: use of or exposure to the product may cause temporary or medically reversible health problems, or the chance of serious harm is remote.
Is this recall still active?
The FDA lists the recall as ongoing. The recall is still in progress.

Source: U.S. Food and Drug Administration, openFDA enforcement report · Last updated 10/14/2026 · Do not rely on openFDA to make decisions regarding medical care